Open AccessAnalysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab
Author(s) -
Qing Zhu,
Josie McAuliffe,
Nita Patel,
Frances J. Palmer-Hill,
Chin-Fen Yang,
Brandon Liang,
Lan Su,
Wei Zhu,
Leslie Wachter,
Susan Wilson,
Randall S. MacGill,
Subramaniam Krishnan,
Michael McCarthy,
Genevieve A. Losonsky,
JoAnn Suzich
Publication year - 2011
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiq100
Subject(s) - palivizumab , glutamine , virology , virus , neutralization , monoclonal antibody , biology , asparagine , pneumovirinae , antibody , paramyxoviridae , immunology , viral disease , amino acid , genetics
Palivizumab is a US Food and Drug Administration-approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-risk infants. Motavizumab, derived from palivizumab with enhanced antiviral activity, has recently been tested in humans. Although palivizumab escape mutants have been generated in the laboratory, the development of resistant RSV in patients receiving palivizumab has not been reported previously.